Chimeric Animal Immune Tolerance Breakthrough

The original patent relates to finding and treating inflammation after birth in chimeric animals. However, it is limited to treating immune responses and inflammation after they occur. The present invention addresses the need for a more proactive and personalized approach to inducing immune tolerance, treating inflammation, and modeling human diseases in chimeric animals.

The new claims introduce a paradigm shift in the field by proactively inducing immune tolerance, using precision-guided immunomodulatory therapy, and providing real-time monitoring of immune responses. These advancements are non-obvious and go beyond the original patent's focus on treating immune responses and inflammation after they occur.

Alternative embodiments of the invention could include using different cell types, modifying the cell selection and expansion modules, or integrating the system with other disease modeling platforms. Variations of the invention could also include using the system for modeling different human diseases or developing new therapeutic strategies.

The invention has significant commercial potential in the fields of regenerative medicine, disease research, and personalized medicine. The target market includes pharmaceutical companies, biotech firms, and research institutions seeking to develop novel therapeutics and disease models.